SCHEDULE: TCG Crossover Discloses 9.8% Stake in Altimmune

TCG Crossover and Chen Yu have reported a combined beneficial ownership of 9.8% in Altimmune, Inc. following a recent underwritten offering.

Summary

• TCG Crossover Fund II and Fund III, along with their respective general partners and Chen Yu, have filed a Schedule 13G indicating a 9.8% stake in Altimmune, Inc.
• The holdings consist of 10,000,000 shares of common stock and 10,000,000 shares issuable upon the exercise of common warrants.
• The warrants are subject to a 9.99% beneficial ownership limitation, preventing immediate conversion if it exceeds that threshold.
• The reporting persons acquired these interests following an underwritten offering by the issuer that closed on April 24, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as it reflects significant institutional backing for the company's recent capital raise.

Positives

• Significant institutional investment from TCG Crossover, signaling confidence in the company's long-term prospects.
• The investment follows a successful capital raise by the issuer, strengthening the company's balance sheet.

Negatives

• The presence of warrants creates potential future dilution for existing shareholders upon exercise.

Risks

• Beneficial ownership limitations on warrants restrict the ability of the reporting persons to increase their stake beyond 9.99% without further regulatory compliance.
• Market volatility associated with biotech equity offerings.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional accumulation in biotech firms following public offerings is a common indicator of 'smart money' support for clinical-stage development pipelines.

Comparison to Industry Standards

• The 9.8% stake is consistent with typical institutional block-holding patterns in mid-cap biotechnology companies.
• The use of warrants with ownership caps is a standard mechanism in biotech financing to manage regulatory reporting requirements.

Stakeholder Impact

• Shareholders may view the entry of a major institutional investor as a validation of the company's strategic direction.

Next Steps

• Monitoring of future Form 4 or 13G/A filings for changes in position.

Key Dates

Recommendation

The filing confirms institutional support, which is generally stabilizing, but investors should wait for further clinical or operational milestones before increasing exposure.

Keywords

Altimmune, TCG Crossover, Schedule 13G, Biotech, Institutional Investor, Common Stock, Warrants